BACKGROUND: Glutathione S-transferases (GSTs) are polymorphic enzymes that are responsible for glutathione conjugation of alkylators and scavenging of free radicals created by radiation. GST polymorphisms may result in altered or absent enzyme activity and have been associated with survival in patients with cancer. The authors of this report hypothesized that patients with anaplastic glioma (AG) who have GST genotypes that encode for lower activity enzymes will have longer survival than similar patients who have higher activity genotypes. The current study was performed to investigate the role of GST enzyme polymorphisms in predicting the survival of patients with AG. METHODS: The medical records of 207 patients with AG from a single cancer center were reviewed retrospectively. Polymorphisms for the GST micro1 (GSTM1), GST theta1 (GSTT1), and GST pi1 (GSTP1) enzymes were identified. Overall survival was compared using the Kaplan-Meier method and Cox proportional hazards analyses adjusting for age, sex, histology, and therapy. RESULTS: Among the patients with oligodendroglial tumors (n = 94), patients who had the GSTT1 null genotype had a 2.9 times increased risk of death (95% confidence interval [CI], 1.3-6.3) compared with patients who had the GSTT1 non-null genotype. Adjustment for 1p/19q status did not change the finding. In the patients who had anaplastic astrocytoma (n = 113), the patients with all GSTP1 genotypes except GSTP1 *B/*B had a 3.8 times increased risk of death (95% CI, 0.5-29.6) compared with patients who had the GSTP1 *B/*B genotype. CONCLUSIONS: In patients with anaplastic oligodendroglial tumors, the GSTT1 null genotype may be associated with poor survival, possibly because of modifications in therapy secondary to increased toxicity. This hypothesis is under investigation. In patients with anaplastic astrocytoma, the GSTP1 *B/*B genotype may confer a survival advantage. (c) 2010 American Cancer Society.
BACKGROUND:Glutathione S-transferases (GSTs) are polymorphic enzymes that are responsible for glutathione conjugation of alkylators and scavenging of free radicals created by radiation. GST polymorphisms may result in altered or absent enzyme activity and have been associated with survival in patients with cancer. The authors of this report hypothesized that patients with anaplastic glioma (AG) who have GST genotypes that encode for lower activity enzymes will have longer survival than similar patients who have higher activity genotypes. The current study was performed to investigate the role of GST enzyme polymorphisms in predicting the survival of patients with AG. METHODS: The medical records of 207 patients with AG from a single cancer center were reviewed retrospectively. Polymorphisms for the GST micro1 (GSTM1), GST theta1 (GSTT1), and GST pi1 (GSTP1) enzymes were identified. Overall survival was compared using the Kaplan-Meier method and Cox proportional hazards analyses adjusting for age, sex, histology, and therapy. RESULTS: Among the patients with oligodendroglial tumors (n = 94), patients who had the GSTT1 null genotype had a 2.9 times increased risk of death (95% confidence interval [CI], 1.3-6.3) compared with patients who had the GSTT1 non-null genotype. Adjustment for 1p/19q status did not change the finding. In the patients who had anaplastic astrocytoma (n = 113), the patients with all GSTP1 genotypes except GSTP1 *B/*B had a 3.8 times increased risk of death (95% CI, 0.5-29.6) compared with patients who had the GSTP1 *B/*B genotype. CONCLUSIONS: In patients with anaplastic oligodendroglial tumors, the GSTT1 null genotype may be associated with poor survival, possibly because of modifications in therapy secondary to increased toxicity. This hypothesis is under investigation. In patients with anaplastic astrocytoma, the GSTP1 *B/*B genotype may confer a survival advantage. (c) 2010 American Cancer Society.
Authors: Angela DeMichele; Richard Aplenc; Jeffrey Botbyl; Theresa Colligan; Lisa Wray; Melissa Klein-Cabral; Andrea Foulkes; Phyllis Gimotty; John Glick; Barbara Weber; Edward Stadtmauer; Timothy R Rebbeck Journal: J Clin Oncol Date: 2005-08-20 Impact factor: 44.544
Authors: Sarah L Holley; Ramesh Rajagopal; Paul R Hoban; Mark Deakin; Adeshina S Fawole; James B Elder; Jackie Elder; Victoria Smith; Richard C Strange; Anthony A Fryer Journal: Int J Oncol Date: 2006-01 Impact factor: 5.650
Authors: Jose Claudio C Rocha; Cheng Cheng; Wei Liu; Shinji Kishi; Soma Das; Edwin H Cook; John T Sandlund; Jeffrey Rubnitz; Raul Ribeiro; Dario Campana; Ching-Hon Pui; William E Evans; Mary V Relling Journal: Blood Date: 2005-02-15 Impact factor: 22.113
Authors: Charles Lu; Margaret R Spitz; Hua Zhao; Qiong Dong; Mylene Truong; Joe Y Chang; George R Blumenschein; Waun K Hong; Xifeng Wu Journal: Cancer Date: 2006-01-15 Impact factor: 6.860
Authors: J N Scott; N B Rewcastle; P M Brasher; D Fulton; J A MacKinnon; M Hamilton; J G Cairncross; P Forsyth Journal: Ann Neurol Date: 1999-08 Impact factor: 10.422
Authors: Stefan Hohaus; Annalisa Di Ruscio; Annalaura Di Febo; Giuseppina Massini; Francesco D'Alo'; Francesco Guidi; Giovanna Mansueto; Maria Teresa Voso; Giuseppe Leone Journal: Clin Cancer Res Date: 2005-03-15 Impact factor: 12.531
Authors: Thierry Lecomte; Bruno Landi; Philippe Beaune; Pierre Laurent-Puig; Marie-Anne Loriot Journal: Clin Cancer Res Date: 2006-05-15 Impact factor: 12.531
Authors: E Goekkurt; S Hoehn; C Wolschke; C Wittmer; C Stueber; D K Hossfeld; J Stoehlmacher Journal: Br J Cancer Date: 2006-01-30 Impact factor: 7.640
Authors: Jie Zhang; Zhi-Wei Ye; Danyelle M Townsend; Chanita Hughes-Halbert; Kenneth D Tew Journal: Adv Cancer Res Date: 2019-04-23 Impact factor: 6.242
Authors: Susan Searles Nielsen; Beth A Mueller; Susan Preston-Martin; Federico M Farin; Elizabeth A Holly; Roberta McKean-Cowdin Journal: Cancer Epidemiol Biomarkers Prev Date: 2011-09-13 Impact factor: 4.254
Authors: Kenneth D Tew; Yefim Manevich; Christina Grek; Ying Xiong; Joachim Uys; Danyelle M Townsend Journal: Free Radic Biol Med Date: 2011-04-22 Impact factor: 7.376
Authors: Astrid Weyerbrock; Nadja Osterberg; Nikolaos Psarras; Brunhilde Baumer; Evangelos Kogias; Anna Werres; Stefanie Bette; Joseph E Saavedra; Larry K Keefer; Anna Papazoglou Journal: Neurosurgery Date: 2012-02 Impact factor: 4.654
Authors: Surya Rednam; Michael E Scheurer; Adekunle Adesina; Ching C Lau; Mehmet Fatih Okcu Journal: Pediatr Blood Cancer Date: 2012-10-12 Impact factor: 3.167